Flavia Pease serves as Executive Vice President and Chief Financial Officer at Insulet Corporation, a pioneering medical technology company renowned for its Omnipod tubeless insulin management system. Joining Insulet in September 2021, Pease leads the company's global finance organization, overseeing financial planning and analysis, accounting, tax, treasury, investor relations, and risk management. Her strategic oversight has been instrumental in driving Insulet's financial health amid rapid growth, supporting innovations that empower over 350,000 people with diabetes worldwide. With more than 25 years of finance experience in biopharmaceuticals and healthcare, Pease previously held senior roles at Biogen Inc., including Executive Vice President and Head of Commercial Finance, Chief Financial Officer of Biogen Digital Health, and Senior Vice President of Finance for Hemophilia and Rare Diseases. Before Biogen, she was Senior Vice President and Head of Global Commercial Finance at Shire plc, where she managed finances for a portfolio exceeding $10 billion in revenue. Pease began her career at Deloitte, building a strong foundation in audit, advisory, and financial consulting. Under Pease's leadership, Insulet has delivered exceptional financial performance, including consistent revenue growth surpassing 20% annually, successful capital raises, and a path to sustained profitability. Her expertise in scaling operations and optimizing capital allocation has positioned Insulet for long-term success in the competitive diabetes care market, earning her recognition as a transformative finance leader in medtech.